The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.

[1]  S. Ren,et al.  ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer , 2011, Medical Oncology.

[2]  G. Bepler,et al.  Ribonucleotide reductase subunit M1 expression in resectable, muscle‐invasive urothelial cancer correlates with survival in younger patients , 2010, BJU international.

[3]  Jae Jin Lee,et al.  The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC). , 2010, Lung cancer.

[4]  L. Mao,et al.  Positive expression of ERCC1 predicts a poorer platinum-based treatment outcome in Chinese patients with advanced non-small-cell lung cancer , 2010, Medical oncology.

[5]  E. Giovannetti,et al.  Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer , 2010, The Pharmacogenomics Journal.

[6]  Ugo Boggi,et al.  MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. , 2010, Cancer research.

[7]  C. Zhou,et al.  ERCC1, RRM1, and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. , 2010 .

[8]  Yong-Tae Kim,et al.  Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer , 2010, PloS one.

[9]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[10]  Yi-long Wu,et al.  RRM1 single nucleotide polymorphism -37C→A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy , 2010, Journal of hematology & oncology.

[11]  C. Cass,et al.  Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. , 2010, Biochemical pharmacology.

[12]  Peter M. Ellis,et al.  First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer: A Systematic Review , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[13]  G. Bepler,et al.  In Situ Protein Expression of RRM1, ERCC1, and BRCA1 in Metastatic Breast Cancer Patients Treated with Gemcitabine-Based Chemotherapy , 2009, Cancer investigation.

[14]  N. André,et al.  Cytidine deaminase residual activity in serum is a predictive marker of early severe toxicities in adults after gemcitabine-based chemotherapies. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  V. Mey,et al.  Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer , 2010, Cancer Chemotherapy and Pharmacology.

[16]  J. Kolesar,et al.  A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503 , 2010, Investigational New Drugs.

[17]  G. Peters,et al.  Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models , 2010, Investigational New Drugs.

[18]  G. Reid,et al.  The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. , 2009, Oligonucleotides.

[19]  C. Obasaju,et al.  Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Xin-chen Sun,et al.  Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. , 2009, Lung cancer.

[21]  G. Stephenson,et al.  Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. , 2009, Journal of medicinal chemistry.

[22]  Y. Takeda,et al.  Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma , 2009, Oncogene.

[23]  Tetsuo Arakawa,et al.  Gemcitabine sensitivity-related mRNA expression in endoscopic ultrasound-guided fine-needle aspiration biopsy of unresectable pancreatic cancer , 2009, Journal of experimental & clinical cancer research : CR.

[24]  J. Watson,et al.  Potent subunit-specific effects on cell growth and drug sensitivity from optimised siRNA-mediated silencing of ribonucleotide reductase , 2009, Journal of RNAi and gene silencing : an international journal of RNA and gene targeting research.

[25]  Y. Yen,et al.  Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis , 2009, Molecular Cancer.

[26]  G. Kucera,et al.  Phospholipid/deoxycytidine analogue prodrugs for the treatment of cancer , 2009 .

[27]  大高 和真.  Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma , 2009 .

[28]  R. Rosell,et al.  XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. , 2009, Clinical lung cancer.

[29]  T. Pozzan,et al.  Ribonucleotide reduction is a cytosolic process in mammalian cells independently of DNA damage , 2008, Proceedings of the National Academy of Sciences.

[30]  D. Mavroudis,et al.  Tumor BRCA1, RRM1 and RRM2 mRNA Expression Levels and Clinical Response to First-Line Gemcitabine plus Docetaxel in Non-Small-Cell Lung Cancer Patients , 2008, PloS one.

[31]  P. Couvreur,et al.  Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms , 2008, Anti-cancer drugs.

[32]  C. Obasaju,et al.  Clinical Efficacy and Predictive Molecular Markers of Neoadjuvant Gemcitabine and Pemetrexed in Resectable Non-small Cell Lung Cancer , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[33]  I. Oh,et al.  Efficacy of Gemcitabine in Patients with Non–Small Cell Lung Cancer According to Promoter Polymorphisms of the Ribonucleotide Reductase M1 Gene , 2008, Clinical Cancer Research.

[34]  R. Bronson,et al.  Broad overexpression of ribonucleotide reductase genes in mice specifically induces lung neoplasms. , 2008, Cancer research.

[35]  D. Mavroudis,et al.  Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine , 2008, British Journal of Cancer.

[36]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[37]  Y. Yatabe,et al.  mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines , 2007, Respirology.

[38]  N. Hanna,et al.  RRM1 Modulated In Vitro and In Vivo Efficacy of Gemcitabine and Platinum in Non–Small-Cell Lung Cancer , 2008 .

[39]  G. Peters,et al.  Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. , 2007, Journal of medicinal chemistry.

[40]  Alan Cantor,et al.  Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  G. Pond,et al.  A Phase II study of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) and gemcitabine in advanced pancreatic carcinoma. A trial of the Princess Margaret Hospital Phase II consortium , 2007, Investigational New Drugs.

[42]  J. Roh,et al.  An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. , 2007, The oncologist.

[43]  Y. Takeda,et al.  Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer , 2007, International journal of cancer.

[44]  Zhong Zheng,et al.  DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. , 2007, The New England journal of medicine.

[45]  中野 靖弘,et al.  Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells , 2007 .

[46]  M Volante,et al.  ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  G. Bepler,et al.  RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  R. Ueda,et al.  The determinants of sensitivity and acquired resistance to gemcitabine differ in non–small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity , 2006, Molecular Cancer Therapeutics.

[49]  G. Bepler,et al.  Suppression of lung tumor formation by the regulatory subunit of ribonucleotide reductase. , 2006, Cancer research.

[50]  L. Klotz,et al.  Dose escalation phase of a phase I/II study of GTI-2501, an antisense to the R1 subunit of ribonucleotide reductase (RNR) and docetaxel in patients with metastatic hormone-refractory prostate cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  Hyun Cheol Chung,et al.  Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines , 2006, Pharmacogenetics and genomics.

[52]  M. Taron,et al.  Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Y. Lee,et al.  GTI-2501, an antisense agent targeting R1, the large subunit of human ribonucleotide reductase, shows potent anti-tumor activity against a variety of tumors. , 2006, International journal of oncology.

[54]  Pär Nordlund,et al.  Ribonucleotide reductases. , 2006, Annual review of biochemistry.

[55]  G. Peters,et al.  Expression microarray analysis and oligo array comparative genomic hybridization of acquired gemcitabine resistance in mouse colon reveals selection for chromosomal aberrations. , 2005, Cancer Research.

[56]  Bauke Ylstra,et al.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. , 2005, Cancer research.

[57]  C. Galmarini,et al.  Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells , 2005, Molecular Cancer Therapeutics.

[58]  G. Bepler,et al.  Ribonucleotide reductase M1 gene promoter activity, polymorphisms, population frequencies, and clinical relevance. , 2005, Lung cancer.

[59]  A. Fujioka,et al.  pentofuranosyl)cytosine (ECyd, TAS-106) against an established gemcitabine (dFdCyd)-resistant human pancreatic cancer cell line , 2005 .

[60]  M. Taron,et al.  Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  SUSANA PEREIRA,et al.  Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine , 2004, J. Comput. Chem..

[62]  E. Felip,et al.  Gene Expression as a Predictive Marker of Outcome in Stage IIB-IIIA-IIIB Non-Small Cell Lung Cancer After Induction Gemcitabine-Based Chemotherapy Followed By Resectional Surgery , 2004, Clinical Cancer Research.

[63]  L. Gelbert,et al.  An Increase in the Expression of Ribonucleotide Reductase Large Subunit 1 Is Associated with Gemcitabine Resistance in Non-Small Cell Lung Cancer Cell Lines , 2004, Cancer Research.

[64]  Alan Cantor,et al.  RRM1 and PTEN as prognostic parameters for overall and disease-free survival in patients with non-small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  G. Bepler,et al.  Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients , 2004, Clinical Cancer Research.

[66]  Yun Yen,et al.  Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential , 1998, Clinical & Experimental Metastasis.

[67]  M. Cao,et al.  Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  G. Bepler,et al.  Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancer , 2003, Oncogene.

[69]  G. Bepler,et al.  RRM1-induced metastasis suppression through PTEN-regulated pathways , 2003, Oncogene.

[70]  Y. Yen,et al.  Phase I pharmacodynamic study of time and sequence dependency of hydroxyurea in combination with gemcitabine: a California Cancer Consortium Trial , 2002, Cancer Chemotherapy and Pharmacology.

[71]  G. Bepler,et al.  Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  G. Bepler,et al.  Transcript map and complete genomic sequence for the 310 kb region of minimal allele loss on chromosome segment 11p15.5 in non-small-cell lung cancer , 2001, Oncogene.

[73]  G. Bepler,et al.  Lung cancer and the human gene for ribonucleotide reductase subunit M1 (RRM1) , 1999, Mammalian Genome.

[74]  J. Wright,et al.  The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. , 1998, Cancer research.

[75]  J. Wright,et al.  The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[76]  D. V. Von Hoff,et al.  Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[77]  Y. Yen,et al.  Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. , 1995, Cancer research.

[78]  R. W. Brockman,et al.  Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate. , 1991, Cancer research.

[79]  Y Z Xu,et al.  Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2',2'-difluorodeoxycytidine. , 1990, Molecular pharmacology.

[80]  Y. Wataya,et al.  Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. , 1989, Cancer research.